Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2015

View Archived Issues

Purdue Pharma divulges new opioid receptor agonists

FDA advisory committee completes new review of Fabre-Kramer's gepirone ER

S1P2 receptor antagonist shows promise for fibrosis

Probing the role of FKBP5 in the epigenetic effects of paroxetine

Phase III trial AFFINITY of custirsen in mCRPC to continue following futility analysis

FAK inhibitor GSK-2256098 reaches glioblastoma tumor tissue in patients

Ignyta's entrectinib first drug selected for the SPECTA biomarker screening initiative

Bristol-Myers Squibb discloses HCV NS5B inhibitors

Roche and Genentech present JAK inhibitors

Newron begins U.S. phase II trial of NW-3509 in patients with schizophrenia

Kamada provides update on alpha1-antitrypsin development in type 1 diabetes

Shionogi's Mulpleta launched in Japan

Reinnervate's Alvetex scaffold used in 3D models of skin and neuronal tissue

Atea plans clinical development of new hepatitis C virus polymerase inhibitors

Anti-survivin vaccine induces immune response in phase II trial in DLBCL

GSK launches Nucala in U.S.

Assurex Health expands utility of GeneSight Psychotropic test

Phase I trial results of T1D immunotherapy with autologous polyclonal Tregs

ORIC Pharmaceuticals announces Series B financing

Apricus confirms strategy for fispemifene, following FDA guidance on enclomiphene

Pradigastat reduces liver fat in patients with nonalcoholic fatty liver disease

HiberGene's meningococcal disease diagnostic receives CE Mark

TxCell reacquires full rights to Ovasave

Celleron reports results from first clinical study of HDAC inhibitor CXD-101

FDA places Zafgen's phase III trial of beloranib in Prader-Willi syndrome on full clinical hold

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...